This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.82% per year. These returns cover a period from January 1, 1988 through October 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical: Archive
Cencora Q4 Earnings & Revenues Beat on Specialty Growth, Margins Expand
by Zacks Equity Research
COR's Q4 earnings and revenues beat estimates as specialty drug demand fuels growth and margins expand. The company raises its fiscal 2027 outlook.
CORPositive Net Change MMSIPositive Net Change OPKPositive Net Change GMEDPositive Net Change
earnings medical medical-devices
Reasons to Retain TransMedics Stock in Your Portfolio for Now
by Zacks Equity Research
TMDX's OCS technology, robust pipeline and global expansion support growth prospects, but margin pressures and rising investments remain key concerns.
TMDXPositive Net Change MMSIPositive Net Change OPKPositive Net Change GMEDPositive Net Change
medical medical-devices
Here's Why You Should Retain BTSG Stock in Your Portfolio for Now
by Zacks Equity Research
BrightSpring's specialty pharmacy growth, Provider Services expansion and operational gains fuel optimism, but IRA pressures and integration risks remain.
BTSGNegative Net Change ISRGPositive Net Change GMEDPositive Net Change GKOSPositive Net Change
medical medical-devices
AIG Q3 Earnings Beat Estimates on Strong Premium Growth
by Zacks Equity Research
American International's Q3 2026 earnings beat estimates by 11.4% on premium growth and higher investment income, despite elevated catastrophe losses.
AIGPositive Net Change HIGPositive Net Change AONPositive Net Change EGPositive Net Change
earnings finance insurance medical smart-health
Philips Launches HyperVue Integrated System to Improve PCI Workflows
by Zacks Equity Research
PHG launches HyperVue Integrated in the U.S., combining advanced coronary imaging and AI-driven physiology assessment to streamline cath lab workflows.
PHGPositive Net Change ISRGPositive Net Change GMEDPositive Net Change GKOSPositive Net Change
medical medical-devices
Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up
by Zacks Equity Research
Teva's Q3 earnings beat estimates as strong branded drug sales fueled growth, prompting higher 2026 revenue and product sales guidance.
TEVANegative Net Change BMYPositive Net Change TGTXPositive Net Change TARSNegative Net Change
earnings medical
Are Options Traders Betting on a Big Move in Stryker Stock?
by Zacks Equity Research
Investors need to pay close attention to SYK stock based on the movements in the options market lately.
SYKPositive Net Change
medical
CORT's Q3 Earnings Beat, Higher Product Sales Aid Y/Y Revenues
by Zacks Equity Research
Corcept's Q3 earnings and revenues beat estimates, driven by strong Lifyorli uptake and higher Korlym sales, as the company advances its pipeline.
CORTNegative Net Change RHHBYPositive Net Change TGTXPositive Net Change TARSNegative Net Change
earnings medical
CVS Q3 Earnings & Revenues Top Estimates, Stock Up in Pre-Market
by Zacks Equity Research
CVS Health's Q3 earnings and revenues beat estimates as stronger margins and improved operating performance prompt management to raise its 2026 outlook.
CVSNegative Net Change ISRGPositive Net Change MEDPNegative Net Change BLCOPositive Net Change
earnings medical medical-devices
Charles River Q3 Earnings & Revenues Top Estimates, Stock Rises
by Zacks Equity Research
CRL beats Q3 earnings and revenue estimates as organic growth and margin expansion drive results, prompting the company to raise its 2026 outlook.
CRLNegative Net Change ISRGPositive Net Change MEDPNegative Net Change BLCOPositive Net Change
earnings medical medical-devices